Emma Walmsley, Chief Executive Officer at Gsk, confirmed that the company withdrawn from the process relating to the acquisition of Pfizer’s Consumer Healthcare business.“While we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation”, said Walmsley in a statement. The deal is estimated approx. $ 20 billion and already saw the leave of Reckitt Benckiser and earlier in 2017 of Johnson & Johnson.